Overview

Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes

Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
Data from this pivotal clinical trial will be used to support a marketing application (i.e., NDA) of Navidea's Lymphoseek for use in anatomical delineation of lymphoid tissue (nodes) in the lymphatic pathway draining the primary site of a tumor. Multicenter, open-label, within-patient comparative study of Lymphoseek and vital blue dye in the detection of excised lymph nodes in patients with known melanoma and breast cancer. All patients will receive a single dose of 50 µg Lymphoseek radiolabeled with 0.5 or 2.0 mCi Tc 99m and vital blue dye.
Phase:
Phase 3
Details
Lead Sponsor:
Navidea Biopharmaceuticals
Treatments:
Dextrans
Technetium Tc 99m Pentetate